OY-TES-1表达对肿瘤生物学行为的影响及其抗体血清学分析
|
摘要
我们前期的研究发现癌-睾丸抗原OY-TES-1在肝癌中高表达,在正常组织中限制性表达,并且能够引起机体的体液免疫反应,提示它是一个颇有运用开发前景的靶抗原。本研究初步研究OY-TES-1的表达对肝癌细胞的部分生物学功能的影响;了解恶性肿瘤(结直肠癌)和良性肿瘤(脑膜瘤)中OY-TES-1的表达情况及其抗体出现的情况,探讨将其应用于辅助诊断及肿瘤免疫治疗的可行性。
第一部分OY-TES-1对肝癌细胞生物学行为影响的体外实验研究
目的:构建OY-TES-1真核表达载体pEGFP-N1/OY-TES-1,稳定转染至肝癌细胞株HepG2,体外观察OY-TES-1对HepG2生长、增殖及迁移的的影响。
方法:根据人OY-TES-1基因序列设计引物,以pMAL-C2/OY-TES-1重组质粒作为模板进行PCR,扩增出OY-TES-1编码区cDNA,并与pEGFP-N1质粒连接,构建成pEGFP-N1/OY-TES-1重组质粒,经DNA测序鉴定后,用Fugene HD将重组质粒转染至OY-TES-1表达阴性的肝癌细胞株HepG2。G418筛选阳性克隆并扩增、培养、传代,获得稳定转染株。分别用稳定表达重组质粒pEGFP-N1/OY-TES-1、空质粒pEGFP-N1及未转染的HepG2,通过细胞计数、MTT比色法、平板克隆形成、细胞周期测定和划痕修复等一系列细胞功能学实验,观察获得OY-TES-1表达后的HepG2细胞其生长、增殖和迁移改变。
结果:测序及序列比对证实,pEGFP-N1/OY-TES-1真核表达载体中插入OY-TES-1的基因序列完全正确。RT-PCR和IHC结果显示:在pEGFP-N1/OY-TES-1重组质粒稳定转染的HepG2细胞中,OY-TES-1的表达较空质粒转染细胞和未转染细胞增强。对pEGFP-N1/OY-TES-1重组质粒和pEGFP-N1空质粒转染及未转染的HepG2细胞进行检测,发现OY-TES-1的转染对HepG2的生长、增殖及迁移能力无明显影响。
结论:成功构建了pEGFP-N1/OY-TES-1真核表达载体,OY-TES-1对肝癌细胞株HepG2的生长、增殖及迁移无明显影响。
第二部分OY-TES-1在结直肠癌和脑膜瘤的表达及临床意义分析
目的:研究OY-TES-1在结直肠癌和脑膜瘤的表达及临床意义。
方法:采用RT-PCR和IHC方法,分别检测24例腺瘤组织、60例结直肠癌及相应的癌旁组织、45例脑膜瘤组织OY-TES-1mRNA和蛋白质;结合临床病理资料对实验结果进行统计分析。
结果: RT-PCR结果显示,结直肠癌OY-TES-1mRNA阳性率为73.3%,明显高于癌旁组织(55.0%)和腺瘤组织(45.8%)(P<0.05);脑膜瘤OY-TES-1mRNA阳性率为66.7%。免疫组织化学法检测发现,OY-TES-1蛋白在腺瘤组织和结直肠癌癌旁组织中均无表达,结直肠癌和脑膜瘤OY-TES-1蛋白阳性率分别为43.3%和40.0%。统计学分析结果显示,结直肠癌OY-TES-1蛋白的表达与浸润深度和组织分化程度相关(P<0.05),与年龄、性别、组织类型、发病部位、肿瘤大小、淋巴结转移、远处转移、TNM分期及Duke’s分期无关;脑膜瘤中OY-TES-1的表达与年龄、性别及组织类型均无关。
结论:OY-TES-1蛋白较之其mRNA更具有限制性表达的特点。OY-TES-1蛋白主要在进展期结直肠癌中表达,其表达可能与肿瘤的演进和恶化有关;结直肠癌和脑膜瘤中OY-TES-1的表达均较高,而癌旁组织和癌前病变组织不表达,OY-TES-1对于肿瘤的辅助诊断及免疫治疗可能具有潜在的应用价值。
第三部分结直肠癌和脑膜瘤患者血清OY-TES-1抗体的检测
目的:了解结直肠癌和脑膜瘤患者血清中OY-TES-1抗体的出现情况,探讨OY-TES-1血清抗体出现的临床意义。
方法:采用ELISA检测25例结肠癌和31例脑膜瘤患者血清中相应的OY-TES-1抗体,以50例正常人血清作为对照。结合临床病理资料对实验结果进行统计分析。
结果:ELISA检测未发现正常人血清中有OY-TES-1抗体,结直肠癌和脑膜瘤患者血清抗体阳性率分别为8%和16.3%。OY-TES-1血清抗体的出现与临床资料无明显关系。
结论:OY-TES-1在部分结直肠癌和脑膜瘤患者血清出现特异性抗体,其意义尚需进一步的探讨。
Our previous study found that cancer-testis antigen OY-TES-1 was highly expressed in liver cancer, restrictively expressed in normal tissues. There was humoral immune response against OY-TES-1 in cancer patients . It is suggested that it may be a promising target antigen . This study will focuse on elucidating the some of biological function of tumor cells with OY-TES-1 expression, understaning the expression of OY-TES-1 in malignant (coloretal cancer) and benign tumor (meningioma), and humoral response in those patients. The results will help to evaluate the feasibility for immunotherapy of OY-TES-1.
Part 1 In vitro experimental study of OY-TES-1 expression in cancer cell effecting on its biological function
AIM: To construct the eukaryotic expression vector pEGFP-N1/OY-TES-1 which then transfect stably into hepatocellular carcinoma cell line HepG2. Transfected cells will be observed in vitro for their growth, proliferation and migration.
METHODS: Primers were designed according to the sequence of OY-TES-1 gene in human. Recombinant pMAL-C2/OY-TES-1 was used as a template for amplifing OY-TES-1 cDNA coding region. The PCR product was ligated into pEGFP-N1 vector to construct a recombinant pEGFP-N1/OY-TES-1 identified by DNA sequencing. With Fugene HD reagent, pEGFP-N1/OY-TES-1 was transfected into HepG2 cells that are OY-TES-1 negative expression. Positive clones were screened by using G418, which resulted in gain of cells with stable expression of OY-TES-1. HepG2 cells transfected with pEGFP-N1/OY-TES-1, pEGFP-N1 and untransfected cells, respectively, were tested for their function by cell counting, MTT growth test, plate clone forming, cell cycle detecting and wound-healing experiment.
RESULTS: Sequencing result by blast search was confirmed that insertion of OY-TES-1 gene was correct. RT-PCR and immunohistochemistry showed that OY-TES-1 expression in both mRNA and protein lever was higher in cells transfected by pEGFP-N1/OY-TES-1 than un-transfected and transfected by pEGFP-N1 vector only. Through the tests of cell counting, MTT growth test, plate clone formatting, cell cycle detecting and wound-healing experiment, it seems that pEGFP-N1/OY-TES-1 transfected cells do not change in growth, proliferation, cell cycle and migration.
CONCLUSIONS: pEGFP-N1/OY-TES-1 eukaryotic expression vector was constructed successfully. It seems that OY-TES-1 had no effect on growth, proliferation, cell cycle and migration in hepatocellular carcinoma cell line HepG2.
Part 2 Expression of OY-TES-1 in colorectal cancer and meningioma with its clinical significance
AIM: To investigate the expression of OY-TES-1 expression in colorectal cancer and meningioma, and to explore its significance.
METHODS: RT-PCR and immunohistochemistry were used to detect the expression level of mRNA and protein of OY-TES-1 gene, respectively, in 24 adenoma tissues, 60 colorectal cancer tissues and adjacent noncancerous tissues as well as 45 meningioma tissues. Statistic analysis was performed combining OY-TES-1expression of and patients’clinico- pathological features.
RESULTS: 73.3% of OY-TES-1 was expressed in colorectal cancer tissues, which was significantly higher than that in adjacent noncancerous tissues (55.0%) and adenomas (45.8%) (P <0.05). The meningioma tissues showed 66.7% of OY-TES-1 mRNA expression. There was no OY-TES-1 protein expression in adenoma and non-cancerous tissues of adjacent colorectal cancer. The positive rate of OY-TES-1 protein expression was 43.3% and 40.0% in colorectal cancer tissues and meningioma tissues, respectively. The OY-TES-1 protein expression in colorectal cancer tissues was significantly associated with depth of invasion and degree of differentiation, and not associated with age, gender, histological type, anatomical site, tumor size, lymph node metastasis, distant metastasis, TNM stage and Duke's stages. There were no significantly differences in OY-TES-1 expression with age, sex and histological type in meningioma.
CONCLUSIONS: It is suggested that OY-TES-1 protein had a stricter expression than its mRNA. OY-TES-1 protein was mainly expressed in advanced tumors, and its expression may be related to tumor evolution and malignance. With higher OY-TES-1 expression in both colorectal cancer and meningioma and negative OY-TES-1 expression in non-cancerous tissues,OY-TES-1 may be a useful antigen for tumor auxiliary prognosis.
Part 3 Seroreactivity against OY-TES-1 in colorectal cancer and meningioma
AIM: To investigate seroreactivity against OY-TES-1 in colorectal cancer and meningioma, and to explore its clinical significance.
METHODS: ELISA was used to detect OY-TES-1 serum antibody in 25 colorectal cancer, 31 meningioma patients and 50 normal donors as control. OY-TES-1 serum immunoreactivity and clinical features were statistically analyzed.
RESULTS: The OY-TES-1 antibody was detected in 8.0% of colorectal cancer patients’and in 16.3% of meningioma patients’sera, while no serum reactivity was detected in 50 normal donors. There were no significantly differences between OY-TES-1 serum immunoreactivity and clinical features of patients.
CONCLUSIONS: Seroactivity against OY-TES-1 presents specifically in patients with colorectal cancer and meningioma. The significance of OY-TES-1 antibody in patients needs to further explore.
第一部分OY-TES-1对肝癌细胞生物学行为影响的体外实验研究
目的:构建OY-TES-1真核表达载体pEGFP-N1/OY-TES-1,稳定转染至肝癌细胞株HepG2,体外观察OY-TES-1对HepG2生长、增殖及迁移的的影响。
方法:根据人OY-TES-1基因序列设计引物,以pMAL-C2/OY-TES-1重组质粒作为模板进行PCR,扩增出OY-TES-1编码区cDNA,并与pEGFP-N1质粒连接,构建成pEGFP-N1/OY-TES-1重组质粒,经DNA测序鉴定后,用Fugene HD将重组质粒转染至OY-TES-1表达阴性的肝癌细胞株HepG2。G418筛选阳性克隆并扩增、培养、传代,获得稳定转染株。分别用稳定表达重组质粒pEGFP-N1/OY-TES-1、空质粒pEGFP-N1及未转染的HepG2,通过细胞计数、MTT比色法、平板克隆形成、细胞周期测定和划痕修复等一系列细胞功能学实验,观察获得OY-TES-1表达后的HepG2细胞其生长、增殖和迁移改变。
结果:测序及序列比对证实,pEGFP-N1/OY-TES-1真核表达载体中插入OY-TES-1的基因序列完全正确。RT-PCR和IHC结果显示:在pEGFP-N1/OY-TES-1重组质粒稳定转染的HepG2细胞中,OY-TES-1的表达较空质粒转染细胞和未转染细胞增强。对pEGFP-N1/OY-TES-1重组质粒和pEGFP-N1空质粒转染及未转染的HepG2细胞进行检测,发现OY-TES-1的转染对HepG2的生长、增殖及迁移能力无明显影响。
结论:成功构建了pEGFP-N1/OY-TES-1真核表达载体,OY-TES-1对肝癌细胞株HepG2的生长、增殖及迁移无明显影响。
第二部分OY-TES-1在结直肠癌和脑膜瘤的表达及临床意义分析
目的:研究OY-TES-1在结直肠癌和脑膜瘤的表达及临床意义。
方法:采用RT-PCR和IHC方法,分别检测24例腺瘤组织、60例结直肠癌及相应的癌旁组织、45例脑膜瘤组织OY-TES-1mRNA和蛋白质;结合临床病理资料对实验结果进行统计分析。
结果: RT-PCR结果显示,结直肠癌OY-TES-1mRNA阳性率为73.3%,明显高于癌旁组织(55.0%)和腺瘤组织(45.8%)(P<0.05);脑膜瘤OY-TES-1mRNA阳性率为66.7%。免疫组织化学法检测发现,OY-TES-1蛋白在腺瘤组织和结直肠癌癌旁组织中均无表达,结直肠癌和脑膜瘤OY-TES-1蛋白阳性率分别为43.3%和40.0%。统计学分析结果显示,结直肠癌OY-TES-1蛋白的表达与浸润深度和组织分化程度相关(P<0.05),与年龄、性别、组织类型、发病部位、肿瘤大小、淋巴结转移、远处转移、TNM分期及Duke’s分期无关;脑膜瘤中OY-TES-1的表达与年龄、性别及组织类型均无关。
结论:OY-TES-1蛋白较之其mRNA更具有限制性表达的特点。OY-TES-1蛋白主要在进展期结直肠癌中表达,其表达可能与肿瘤的演进和恶化有关;结直肠癌和脑膜瘤中OY-TES-1的表达均较高,而癌旁组织和癌前病变组织不表达,OY-TES-1对于肿瘤的辅助诊断及免疫治疗可能具有潜在的应用价值。
第三部分结直肠癌和脑膜瘤患者血清OY-TES-1抗体的检测
目的:了解结直肠癌和脑膜瘤患者血清中OY-TES-1抗体的出现情况,探讨OY-TES-1血清抗体出现的临床意义。
方法:采用ELISA检测25例结肠癌和31例脑膜瘤患者血清中相应的OY-TES-1抗体,以50例正常人血清作为对照。结合临床病理资料对实验结果进行统计分析。
结果:ELISA检测未发现正常人血清中有OY-TES-1抗体,结直肠癌和脑膜瘤患者血清抗体阳性率分别为8%和16.3%。OY-TES-1血清抗体的出现与临床资料无明显关系。
结论:OY-TES-1在部分结直肠癌和脑膜瘤患者血清出现特异性抗体,其意义尚需进一步的探讨。
Our previous study found that cancer-testis antigen OY-TES-1 was highly expressed in liver cancer, restrictively expressed in normal tissues. There was humoral immune response against OY-TES-1 in cancer patients . It is suggested that it may be a promising target antigen . This study will focuse on elucidating the some of biological function of tumor cells with OY-TES-1 expression, understaning the expression of OY-TES-1 in malignant (coloretal cancer) and benign tumor (meningioma), and humoral response in those patients. The results will help to evaluate the feasibility for immunotherapy of OY-TES-1.
Part 1 In vitro experimental study of OY-TES-1 expression in cancer cell effecting on its biological function
AIM: To construct the eukaryotic expression vector pEGFP-N1/OY-TES-1 which then transfect stably into hepatocellular carcinoma cell line HepG2. Transfected cells will be observed in vitro for their growth, proliferation and migration.
METHODS: Primers were designed according to the sequence of OY-TES-1 gene in human. Recombinant pMAL-C2/OY-TES-1 was used as a template for amplifing OY-TES-1 cDNA coding region. The PCR product was ligated into pEGFP-N1 vector to construct a recombinant pEGFP-N1/OY-TES-1 identified by DNA sequencing. With Fugene HD reagent, pEGFP-N1/OY-TES-1 was transfected into HepG2 cells that are OY-TES-1 negative expression. Positive clones were screened by using G418, which resulted in gain of cells with stable expression of OY-TES-1. HepG2 cells transfected with pEGFP-N1/OY-TES-1, pEGFP-N1 and untransfected cells, respectively, were tested for their function by cell counting, MTT growth test, plate clone forming, cell cycle detecting and wound-healing experiment.
RESULTS: Sequencing result by blast search was confirmed that insertion of OY-TES-1 gene was correct. RT-PCR and immunohistochemistry showed that OY-TES-1 expression in both mRNA and protein lever was higher in cells transfected by pEGFP-N1/OY-TES-1 than un-transfected and transfected by pEGFP-N1 vector only. Through the tests of cell counting, MTT growth test, plate clone formatting, cell cycle detecting and wound-healing experiment, it seems that pEGFP-N1/OY-TES-1 transfected cells do not change in growth, proliferation, cell cycle and migration.
CONCLUSIONS: pEGFP-N1/OY-TES-1 eukaryotic expression vector was constructed successfully. It seems that OY-TES-1 had no effect on growth, proliferation, cell cycle and migration in hepatocellular carcinoma cell line HepG2.
Part 2 Expression of OY-TES-1 in colorectal cancer and meningioma with its clinical significance
AIM: To investigate the expression of OY-TES-1 expression in colorectal cancer and meningioma, and to explore its significance.
METHODS: RT-PCR and immunohistochemistry were used to detect the expression level of mRNA and protein of OY-TES-1 gene, respectively, in 24 adenoma tissues, 60 colorectal cancer tissues and adjacent noncancerous tissues as well as 45 meningioma tissues. Statistic analysis was performed combining OY-TES-1expression of and patients’clinico- pathological features.
RESULTS: 73.3% of OY-TES-1 was expressed in colorectal cancer tissues, which was significantly higher than that in adjacent noncancerous tissues (55.0%) and adenomas (45.8%) (P <0.05). The meningioma tissues showed 66.7% of OY-TES-1 mRNA expression. There was no OY-TES-1 protein expression in adenoma and non-cancerous tissues of adjacent colorectal cancer. The positive rate of OY-TES-1 protein expression was 43.3% and 40.0% in colorectal cancer tissues and meningioma tissues, respectively. The OY-TES-1 protein expression in colorectal cancer tissues was significantly associated with depth of invasion and degree of differentiation, and not associated with age, gender, histological type, anatomical site, tumor size, lymph node metastasis, distant metastasis, TNM stage and Duke's stages. There were no significantly differences in OY-TES-1 expression with age, sex and histological type in meningioma.
CONCLUSIONS: It is suggested that OY-TES-1 protein had a stricter expression than its mRNA. OY-TES-1 protein was mainly expressed in advanced tumors, and its expression may be related to tumor evolution and malignance. With higher OY-TES-1 expression in both colorectal cancer and meningioma and negative OY-TES-1 expression in non-cancerous tissues,OY-TES-1 may be a useful antigen for tumor auxiliary prognosis.
Part 3 Seroreactivity against OY-TES-1 in colorectal cancer and meningioma
AIM: To investigate seroreactivity against OY-TES-1 in colorectal cancer and meningioma, and to explore its clinical significance.
METHODS: ELISA was used to detect OY-TES-1 serum antibody in 25 colorectal cancer, 31 meningioma patients and 50 normal donors as control. OY-TES-1 serum immunoreactivity and clinical features were statistically analyzed.
RESULTS: The OY-TES-1 antibody was detected in 8.0% of colorectal cancer patients’and in 16.3% of meningioma patients’sera, while no serum reactivity was detected in 50 normal donors. There were no significantly differences between OY-TES-1 serum immunoreactivity and clinical features of patients.
CONCLUSIONS: Seroactivity against OY-TES-1 presents specifically in patients with colorectal cancer and meningioma. The significance of OY-TES-1 antibody in patients needs to further explore.
引文
1. Almeida LG, Sakabe NJ, Oliveira AR, et al. CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res, 2009, 37: D816-819
2. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA, 1997, 94: 1914-1910
3. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun, 2004, 4: 1
4. Old LJ. Cancer vaccine collaborative 2002: Opening address. Cancer Immun, 2003, 3(Suppl 1): 1
5. Ono T, Kurashige T, Harada N, et al. Identification binding protein sp32 precursor as a human cancer/testis antigen. Proc Natl Acad Sci USA, 2001, 98(6): 3282-3287
6. Baba T, Michikawa Y, Kashiwabara S, et al. Proacrosin activation in the presence of a 32-kDa protein from boar spermatozoa. Biochem Biophys Res Commun, 1989,160(3): 1026 -1032
7. Baba T, Niida Y, Michikawa Y, et al. An acrosomal protein, sp32, in mammalian sperm is a binding protein specific for two proacrosins and an acrosin intermediate. J Biol Chem. 1994, 269(13): 10133-10140
8. Tardif S, DubéC, Chevalier S, et al. Capacitation is associated with tyrosine phosphorylation and tyrosine kinase-like activity of pig sperm proteins. Biol Reprod, 2001, 65(3): 784 -792
9.范蓉,罗彬,谢小薰.精子蛋白32研究进展.解剖学杂志. 2007, 30(4): 503-505
10. Kubuschok B, Xie X, Jesnowski R, et al. Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis. Int J Cancer, 2004, 109(4): 568-575
11.范蓉,肖绍文,何少健,等.精子蛋白Sp32/OY-TES-1基因mRNA表达的初步研究.解剖学报, 2006, 37(1): 102-105
12. Hofmann O, Caballero OL, Stevenson BJ, et al. Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A. 2008, 105(51): 20422-20427
13.范蓉,余良,肖绍文,等.实时荧光定量PCR分析精子蛋白Sp32/OY-TES-1基因在正常组织的表达.解剖学报, 2007, 30(4): 81-84
14. Tammela J, Uenaka A, Ono T, et al. OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer. Int J Oncol, 2006, 29(4): 903-910
15.王峰,范蓉,莫发荣,等.癌-睾丸抗原OY-TES-1基因的克隆、表达及纯化.中国免疫学杂志, 2006, 22(12): 16-19
16.范蓉,肖绍文,黄巍,等.癌-睾丸抗原OY-TES-1多克隆抗体的制备及鉴定.中国生物制品学杂志, 2009, 22(8): 804-807
17.范蓉,黄巍,肖绍文,等. OY-TES-1在肝细胞癌中的表达及抗体血清学分析.世界华人消化杂志, 2009, 17(32): 3307-3312
18.范蓉.癌-睾丸抗原OY-TES-1基因重组、表达及抗体血清学分析[博士学位论文].广西医科大学, 2007
19. Okumura H, Nagushi Y, Uanaha A, et al. Identification of an HLA-A24-restricted OY-TES-1 epitope recognized by cytotoxic T cell.Microbiol Immunol, 2005, 49(11): 1009-1016
20. Cronwright G, Le Blanc K, Gotherstrom C, et al. Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSXimpairs cell migration and matrix metalloproteinase 2 expression. Cancer Res, 2005, 65(6): 2207-2215
21. Cilensek ZM, Yehiely F, Kular RK, et al. A member of the GAGE family of tumor antigens is an anti-apoptotic gene that confers resistance to Fas/CD95/APO-1, Interferon-gamma, taxol and gamma-irradiation. Cancer Biol Ther. 2002, 1(4): 380-387
22. Kular RK, Yehiely F, Kotlo KU, et al. GAGE, an antiapoptotic protein binds and modulates the expression of nucleophosmin/B23 and interferon regulatory factor 1. J Interferon Cytokine Res, 2009, 29(10): 645-655
23.蔡三军主编.结直肠肛管癌.北京:北京大学医学出版社, 2006, 11-365
24. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell, 1996, 87(2): 159-170
25.何理盛主编.脑膜瘤.北京:人民卫生出版社, 2003, 4-224
26. Peng JR, Chen HS, Mou DC, et al. Expression of cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and its correlation with clinical parameters. Cancer Lett, 2005, 219(2): 223-232
27. Grizzi F, Franceschini B, Hamrick C, et al. Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma. J Transl Med, 2007, 5: 3
28. Gure AO, Stockert E, Arden KC, et al. CT10: a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational difference analysis. Int J Cancer, 2000, 85: 726-732
29.冯作化主编.医学分子生物学.北京:人民卫生出版社,2005, 175-190
30. http://www.clontech.com/images/pt/dis_vectors/PT3233-5.pdf
31. Zhang J,Cmapbeu RE,Ting AY,et al. Creating new fluorescent probe so freel biology. Nat Rev Mol Cel lBiol, 2002, 3: 906-918
32. Kozak M.Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell, 1986, 44(2): 283-292
33. Kozak M. At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J Mol Biol, 1987,196(4): 947-950
34. Kozak M. Pushing the limits of the scanning mechanism for initiation of translation. Gene, 2002, 299(1-2): 1-34
35.高川,王惠芳,张靖.脂质体介导转染法的原理与应用.生命的化学, 2002, 22(1): 73-75
36.吴海霞,张维铭,李晓眠.基因转染技术的现状与发展.国际生物医学工程杂志, 2007, 30(6): 376-379
37. Calvin S, Calvin JE, Wang J,et al. FuGENE?? HD Transfection Reagent: Choice of a Transfection Reagent with Minimal Off-Target Effect as Analyzed by Microarray Transcriptional Profiling. Biochemica, 2006, 4: 22-26
38. Jacobsen L, Calvin S, Lobenhofer E, et al. Transcriptional effects of transfection: the potential for misinterpretation of gene expression data generated from transiently transfected cells. Biotechniques, 2009, 47(1): 617-624
39.邵英光,李京华,魏桂林,等.内毒素的去除策略.广州化学, 2003, 28(2): 36-45
40. Calvin S, Pitz S, Jacobsen L. Enabling Cancer Research with FuGENE? HD Transfection Reagent. Biochemica, 2007, 2: 26-29
41. Fillion-FortěV, Mounier C. Optimization of transfection efficiency in chick embryo hepatocytes and HepG2 cells. Biochemica, 2007, 1: 13-15
42.姜泊,张亚历,周殿元主编.分子生物学常用实验方法.北京:人民军医出版社, 1996, 159
43.鄂征主编.组织培养技术及其在医学研究中的作用.北京:中国协和医学大学出版社, 2004, 10-133
44. Van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 1991, 254(5038): 1643-1647
45.范蓉,罗昱,肖绍文.肿瘤-睾丸抗原的特性及临床应用.国外医学肿瘤学分册, 2005, 32(3): 166-169
46. Laduron S, Dep lus R, Zhou S, et al. MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucleic Acids Res, 2004, 32 (14) : 4340-4350
47. Sakurai T, Itoh K, Higashitsuji H, et al. A cleaved form of MAGE-A4 binds to Miz-1 and induces apoptosis in human cells. J Biol Chem, 2004, 279(15): 15505-15514
48. Nagao T, Higashitsuji H, Nonoguchi K, et al. MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity. J Biol Chem, 2003, 278(12): 10668-10674
49. Peikert T, Specks U, Farver C, et al. Melanoma antigen A4 is expressed in non-small cell lung cancers and promotes apoptosis. Cancer Res, 2006, 66(9): 4693-4700
50. Li J, Tsai MD. Novel insights into the INK4-CDK4/6-Rb pathway: counter action of gankyrin against INK4 proteins regulates the CDK4-mediated phosphorylation of Rb. Biochemistry, 2002, 41(12): 3977-3983
51. Simpson AJ, Caballero OL, Jungbluth A, et al. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer, 2005, 5(8): 615-625
52. Kular RK, Yehiely F, Kotlo KU, et al. GAGE, an antiapoptotic protein bindsand modulates the expression of nucleophosmin/B23 and interferon regulatory factor 1. J Interferon Cytokine Res, 2009, 29(10): 645-655
53. Shim H, Shim IE, Lee H, et al. CAGE, a novel cancer/testis antigen gene, promotes cell motility by activating ERK and p38 MAPK and down regulating ROS. Mol Cells, 2006, 21 (3): 367-371
54. Shim H, Lee H, Jeoung D. Cancer/testis antigen cancer-associated gene (CAGE) promotes motility of cancer cells through activation of focal adhesion kinase (FAK). Biotechnol Lett, 2006, 28(24): 2057-2063
55. Kim Y, Jeoung D. The cancer/testis antigen CAGE induces MMP-2 through the activation of NF-kappaB and AP-1. BMB Rep. 2009, 42(11): 758-763
56. Duan Z, Duan Y, Lamendola DE, et al. Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res, 2003, 9(7): 2778-2785
57.宋玉亮,彭思扬,王晨滔. XAGE-1b腺病毒表达载体的构建及其功能研究.复旦学报(自然科学版), 2008, 47(3): 318-324
58.曾益新主编.肿瘤学.第二版.北京:人民卫生出版社, 2003,157-158
59.宋今丹主编.医学细胞分子生物学.北京:人民卫生出版社, 2003, 389
60. AJCC. AJCC cancer staging manual. Fifth edition. Philadelphia: Lippincott, 1997
61. Dukes CE. Cancer of the rectum: an analysis of 1000 cases. J. Pathol Bacteriol, 1940, 50: 527
62. Shimizu M, Saitoh Y, Itoh H. Immunohistochemical staining of Ha-ras oncogene product in normal, benign, and malignant human pancreatic tissue. Hum Pathol, 1990, 21(6):607-612
63. Kr?mer BF, Schoor O, Krüger T, et al. MAGED4-expression in renal cell carcinoma and identification of an HLA-A*25-restricted MHC class I ligandfrom solid tumor tissue. Cancer Biol Ther. 2005, 4(9):943-948
64.邢传平,刘斌,董亮.免疫组织化学标记结果的判断方法.中华病理学杂志, 2001, 30(4): 318
65.许良中,杨文涛.免疫组织化学反应结果的判断标准.中国癌症杂志, 1996, 6(4): 229-231
66. Parkin DM. Global cancer statistics in the year 2000. Laucet Oncol, 2001, 2: 533-543
67. Chen Z, Li M, Yuan Y, et al. Cancer/testis antigens and clinical risk factors for liver metastasis of colorectal cancer: a predictive panel. Dis Colon Rectum, 2010, 53(1): 31-38
68. Burgdorf SK, Fischer A, Myschetzky PS, et al. Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine. Oncol Rep, 2008, 20(6): 1305-1311
69. Alves PM, Lévy N, Bouzourene H, Viatte S, et al. Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer. Cancer Immunol Immunother, 2007, 56(6):839-847
70. Dakshinamurthy AG, Ramesar R, Goldberg P, et al. Infrequent and low expression of cancer-testis antigens located on the X chromosome in colorectal cancer: implications for immunotherapy in South African populations. Biotechnol J, 2008,3(11): 1417-1423
71.熊永炎,宗永生.肿瘤异质性研究进展.国外医学肿瘤学分册, 1992, 19(4): 208-211
72. Berchuck A,Olt GJ,Soisson AP,et al. Heterogeneity of antigen expression in advanced epithelial ovarian cancer. Am J Obstet Gynecol,1990,162(4):883-888
73. KariyamaK,Higashi T, KobayashiY,et al. Expression of MAGE-1 and -3 genes and gene products in human hepatocellular carcinoma. Br J Cancer,1999, 81(6): 1080-1087
74. Alves PM, Lévy N, Bouzourene H, et al. Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer. Cancer Immunol Immunother, 2007, 56(6): 839-847
75.李世荣主编,大肠癌—早期诊断、治疗和预防.北京:科学出版社, 2000, 81
76. Norden AD, Drappatz J, Wen PY. Advances in meningioma therapy. Curr Neurol Neurosci Rep, 2009, 9(3): 231-240
77. Rockhill J, Mrugala M, Chamberlain MC. Intracranial meningiomas: an overview of diagnosis and treatment. Neurosurg Focus, 2007, 23(4): E1
78.黄文清主编.神经肿瘤病理学(第二版).军事医学科学出版社,北京, 2001, 479-506
79.王峰,范蓉,谢小薰.CT抗原-神经系统肿瘤免疫治疗的新靶向.肿瘤防治研究, 2007, 34(2): 154-156
80. Sahin U, Koslowski M, Türeci O, et al. Expression of cancer testis genes in human brain tumors. Clin Cancer Res, 2000, 6(10):3916-3922
81. Lee MH, Son EI, Kim E, et al. Expression of cancer-testis genes in brain tumors. J Korean Neurosurg Soc, 2008, 43(4): 190-193
82. Chi DD, Merchant RE, Rand R, et al. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol, 1997, 150(6): 2143-2152
83. Grizzi F, Gaetani P, Franceschini B, et al. Sperm protein 17 is expressed in human nervous system tumours. BMC Cancer. 2006, 6: 23
84.高飞,由田,吕晶玉,等. CAGE基因在颅脑肿瘤中的表达及其机制.癌变畸变突变, 19(3): 239-241
85.范蓉,肖绍文,罗昱,等.癌-睾丸抗原基因NY-SAR-35在人脑膜瘤中的表达.中华神经外科杂志, 2005, 21(2): 109
86. John R. Crowther. The ELISA Guidebook, USA: Humana Press Inc, 2001, 131
87. Houghton AN, Guevara-Patino JA. Immune recognition of self in immunity against cancer. J Clin Invest, 2004,114(4): 551-559
88. Fernandez Madrid F, Tang N, Alansari H, et al. Autoantibodies to Annexin XI-A and Other Autoantigens in the Diagnosis of Breast Cancer. Cancer Res, 2004, 64(15): 5089-5096
89. Coronella JA, Hersh EM. Naturally occurring B cell responses to breast cancer. Cancer Immunol Immunother, 2003, 52(12): 715-738
90.冉宇靓,胡海,赵泽国,等.结肠癌肿瘤自身抗体谱筛选及其应用.肿瘤防治研究, 2008, 35(5): 328-331, 346
91.吴晓江,王歈,季加孚.胃癌中肿瘤/睾丸抗原的表达研究及NY-ESO-1蛋白的自身抗体检测.北京大学学报, 2005, 37(3): 252-256
92. Mathieu MG, Miles AK, Li G, et al. Cancer/testis antigens for therapeutic use. J BUON, 2009, Suppl 1: S97-102
93. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci, 2009, 100(11): 2014-2021
94. Ghafouri-Fard S, Modarressi MH. Cancer-testis antigens: potential targets for cancer immunotherapy. Arch Iran Med, 2009, 12(4): 395-404
95. Zhou SF, Xie XX, Bin YH, et al. ,Identification of HCC-22-5 tumor-associated antigen and antibody response in patients. Clin Chim Acta, 2006, 366(1-2): 274-280
96.谢小薰,王延伟,黎鹏,等.肝细胞癌动力素抗体的血清学分析.中华消化杂志, 2003, 23(12): 751-752
97. Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon Rectum, 1994 ,37(3):272-277
98. Chapman MA, Buckley D, Henson DB, et al. Preoperative carcinoembryonic antigen is related to tumour stage and long-term survival in colorectal cancer. Br J Cancer, 1998, 78(10):1346-1349
99. Heckel D, Comtesse N, Brass N, et al. Novel immunogenic antigen homologous to hyaluronidase in meningioma. Hum Mol Genet, 1998, 7(12):1859-1872
100.Comtesse N, Niedermayer I, Glass B, et al.MGEA6 is tumor-specific overexpressed and frequently recognized by patient-serum antibodies. Oncogene, 2002, 21(2): 239-247
101.Comtesse N, Zippel A, Walle S, Complex humoral immune response against a benign tumor: frequent antibody response against specific antigens as diagnostic targets. Proc Natl Acad Sci U S A, 2005, 102(27):9601-9606
102.S?ling A, Plugge EM, Schmitz M, Autoantibodies to the inhibitor of apoptosis protein survivin in patients with brain tumors. nt J Oncol, 2007, 30(1): 123-128
103. Lea IA, Adoyo P, O'Rand MG. Autoimmunogenicity of the human sperm protein Sp17 in vasectomized men and identification of linear B cell epitopes. Fertil Steril. 1997, 67(2): 355-361
104.范蓉,黄巍,肖绍文,等.精子蛋白32(sp32)/OY-TES-1在生精细胞中的分布及其抗体的血清学检测.生殖与避孕, 29(6): 365-369
105.Lu H, Goodell V, Disis ML. Humoral Immunity Directed against Tumor-Associated Antigens As Potential Biomarkers for the Early Diagnosis of Cancer. J Proteome Res. 2008, 7(4): 1388-1394
106.Gadducci A, Ferdeghini M, Buttitta F, et al. Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer. Gynecol Oncol, 1999, 72(1): 76-81
107.Lechpammer M, Lukac J, Lechpammer S, et al. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Int J Colorectal Dis, 2004, 19(2): 114-120
108.J?ger D, Stockert E, Güre AO, et al. Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Res. 2001, 61(5): 2055-2061
109.Stockert E, J?ger E, Chen YT, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med, 1998, 187(8): 1349-1354
110.Jager E, Stocken E, Zidianakis Z, et a1.Humoral immuneresponses of cancer patients agains“tCancer-Testis”antigen NY-ESO-1:correlation with clinical events. Int J Cancer, 1999, 84(5): 506-510
1.石永玉,王宏程,李燕,等.肝癌相关的肿瘤抗原及其编码基因的筛选与分析.科学通报, 2003, 48(6): 1772-1775
2. Shi YY, Wang HC, Yin YH, et al. Identification and analysis of tumour-associated antigens in hepatocellular carcinoma. Br J Cancer, 2005, 92(5): 929-934
3. Zerbini A, Pilli M, Ferrari C, et al. Is there a role for immunotherapy in hepatocellular carcinoma? Dig Liver Dis, 2006, 38(4): 221-225
4. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun, 2004, 4: 1
5. Van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 1991, 254(5038): 1643-1647
6. Ghafouri-Fard S, Modarressi MH. Cancer-testis antigens: potential targets for cancer immunotherapy. Arch Iran Med, 2009, 12(4): 395-404.
7. Almeida LG, Sakabe NJ, Oliveira AR, et al. CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res, 2009, 37: D816-819
8. Simpson AJ, Caballero OL, Jungbluth A, et al. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer, 2005, 5(8): 615-625
9.彭吉润,郭立民,陈红松,等.肿瘤-睾丸抗原与肿瘤免疫治疗.继续医学教育, 2006, 20(9): 45-48
10.杨丽,王建军,郑英.肿瘤/睾丸抗原研究进展.医学研究杂志, 2008, 37(1): 13-16
11. Modarressi MH, Cameron J, Taylor KE, et al. Identification andcharacterisation of a novel gene, TSGA10, expressed in testis. Gene, 2001, 262(1-2): 249-255
12. Modarressi MH, Behnam B, Cheng M, et al. Tsga10 encodes a 65-kilodalton protein that is processed to the 27-kilodalton fibrous sheath protein. Biol Reprod, 2004, 70(3): 608-615
13. Türeci O, Sahin U, Schobert I, et al. The SSX-2 gene, which is involved in the t (X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res, 1996, 56(20): 4766-4772
14. Türeci O, Sahin U, Koslowski M, et al. A novel tumour associated leucine zipper protein targeting to sites of gene transcription and splicing. Oncogene, 2002, 21(24): 3879-3888
15. Pointud JC, Mengus G, Brancorsini S, et al. The intracellular localisation of TAF7L, a paralogue of transcription factor TFIID subunit TAF7, is developmentally regulated during male germ-cell differentiation. J Cell Sci, 2003, 116(Pt 9): 1847-1858
16. Scanlan MJ, Altorki NK, Gure AO, et al. Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. Cancer Lett, 2000, 150(2): 155-164
17. Pivot-Pajot C, Caron C, Govin J, et al. Acetylation-dependent chromatin reorganization by BRDT, a testis-specific bromodomain-containing protein. Mol Cell Biol, 2003, 23(15): 5354-5365
18. Scibetta AG, Santangelo S, Coleman J, et al. Functional analysis of the transcription repressor PLU-1/JARID1B. Mol Cell Biol, 2007, 27(20): 7220-7235
19. Kang Y, Hong JA, Chen GA, et al. Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1expression in lung cancer cells. Oncogene, 2007, 26(30): 4394-4403
20. Herold A, Suyama M, Rodrigues JP, et al. TAP (NXF1) belongs to a multigene family of putative RNA export factors with a conserved modular architecture. Mol Cell Biol, 2000, 20(23): 8996-9008
21. 21. Scanlan MJ, Gordon CM, Williamson B, et al. Identification of cancer/testis genes by database mining and mRNA expression analysis. Int J Cancer, 2002, 98(4): 485-492
22. Krupnik VE, Sharp JD, Jiang C, et al. Functional and structural diversity of the human Dickkopf gene family. Gene, 1999, 238(2): 301-313
23. Laduron S, Dep lus R, Zhou S, et al. MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucleic Acids Res, 2004, 32 (14): 4340-4350
24. Martelange V, De Smet C, De Plaen E, et al. Identification on a human sarcoma of two new genes with tumor-specific expression. Cancer Res, 2000, 60(14): 3848-3855
25. De Jong A, Buchli R, Robbins D. et al. Characterization of sperm protein 17 in human somatic and neoplastic tissue. Cancer Lett, 2002, 186(2): 201-209
26. Kr?tzschmar J, Haendler B, Eberspaecher U, et al. The human cysteine-rich secretory protein (CRISP) family. Primary structure and tissue distribution of CRISP-1, CRISP-2 and CRISP-3. Eur J Biochem, 1996, 236(3): 827-836
27. Shan J, Yuan L, Xiao Q, et al. TSP50, a possible protease in human testes, is activated in breast cancer epithelial cells. Cancer Res, 2002, 62(1): 290-294
28. Koslowski M, Türeci O, Bell C, et al. Multiple splice variants of lactate dehydrogenase C selectively expressed in human cancer. Cancer Res, 2002, 62(22): 6750-6755
29. Cho B, Lim Y, Lee DY, et al. Identification and characterization of a novelcancer/testis antigen gene CAGE. Biochem Biophys Res Commun, 2002, 292(3): 715-726
30. Cilensek ZM, Yehiely F, Kular RK, et al. A member of the GAGE family of tumor antigens is an anti-apoptotic gene that confers resistance to Fas/CD95/APO-1, Interferon-gamma, taxol and gamma-irradiation. Cancer Biol Ther, 2002, 1(4): 380-387
31. Pousette A, Leijonhufvud P, Arver S, et al. Presence of synaptonemal complex protein 1 transversal filament-like protein in human primary spermatocytes. Hum Reprod, 1997, 12(11): 2414-2417
32. Keeney S, Giroux CN, Kleckner N. Meiosis-specific DNA double-strand breaks are catalyzed by Spo11, a member of a widely conserved protein family. Cell, 1997, 88(3): 375-384
33. Luo G, Huang S, Xie X, et al. Expression of cancer-testis genes in human hepatocellular carcinomas. Cancer Immun, 2002, 2: 11
34. Suzuki K, Tsujitani S, Konishi I, et al. Expression of MAGE genes and survival in patients with hepatocellular careinoma. Int J oncol, 1999, 15(6): 1227-1232
35.谢小薰,蓝玲,黎鹏,等.多种癌-睾丸抗原在广西肝细胞癌中的表达.中华消化杂志, 2004, 24(3): 174- 175
36.谢小薰,何少健,肖绍文,等.三种MAGE基因在广西肝细胞癌中的表达.肿瘤, 2005, 25(6): 585-588
37.刘彬彬,叶胜龙,贺平,等. MAGE-1基因在肝细胞性肝癌中的表达.中华肝脏病杂志, 1999, 7(2): 91-93
38.陈红松,覃柳亮,丛旭,等.肿瘤特异性肿瘤/睾丸抗原在肝癌组织中的表达.中国肝脏病杂志, 2003, 11(3): 145-148
39.肖刚,张文敏,张萌,等.肝癌组织中MAGE-Al表达及其临床意义.临床与实验病理学杂志, 2005, 20(3): 332-334
40. Tahara K, Mori M, Sadanaga N, et al. Expression of the MAGE gene family in human hepatocellular carcinoma. Cancer, 1999, 85(6): 1234-1240
41. Peng JR, Chen HS, Mou DC, et al. Expression of cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and its correlation with clinical parameters. Cancer Lett, 2005, 219(2): 223-232
42.蔡胜利,陈红松,王瑜,等.黑色素瘤抗原1基因在肝细胞癌中的表达.中华医学杂志, 1999, 79(9): 668-672
43.蔡胜利,陈红松,王瑜,等.恶性黑色素瘤抗原编码基因MAGE-1在肝细胞癌中表达的研究.中华普通外科杂志, 1999, 14(3): 229-230
44.牟东成,冷希圣,彭润吉,等.黑色素瘤抗原MAGE-B亚家族基因在肝细胞癌中的表达.中华肿瘤杂志, 2004, 26(1): 40-42
45. Zhao L, Mou DC, Leng XS, et al. Expression of cancer-testis antigens in hepatocellular carcinoma. World J Gastroenterol 2004, 10(14): 2034-2038
46. Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol, 1997, 9(5): 684-693
47. Riener MO, Wild PJ, Soll C, et al. Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma. Int J Cancer. 2009, 124(2): 352-357
48.赵飞兰,何少健,黎鹏,等.癌-睾丸抗原GAGE基因mRNA在肝细胞癌表达及临床意义.中华肝脏病杂志, 2006, 14(8): 605-606
49. Wang XY, Chen HS, Luo S, et al. Comparisons for detecting NY-ESO-1 mRNA expression levels in hepatocellular carcinoma tissues. Oncol Rep, 2009, 21(3): 713-719
50.张小静,范蓉,何少健,等.癌-睾丸抗原SSX基因在肝细胞癌中的表达及临床意义.世界华人消化杂志, 2009, 17(19): 2000-2004
51.吴力群,王新建,卢云,等.肝细胞肝癌患者肿瘤/睾丸抗原SSX-1及NY-ESO-1 mRNA的表达意义.世界华人消化杂志, 2005, 13(14): 1673-1678
52.易斌,廖晓峰,杨志芳,等.肿瘤—睾丸抗原SSX1和SSX4 mRNA在肝细胞癌中的表达.华中科技大学学报, 2006, 35(1): 63-65
53. Chen CH, Chen GJ, Lee HS, et al. Expressions of cancer-testis antigens in human hepatocellular carcinomas. Cancer Lett, 2001, 164(2): 189-195
54. Türeci O, Chen YT, Sahin U, et al. Expression of SSX genes in human tumors. Int J Cancer, 1998, 77(1): 19-23
55.吴力群,王新建,张斌.肝细胞癌组织和外周血中肿瘤/睾丸抗原SSX-2和SSX-5的表达.世界华人消化杂志, 2005, 13(14): 1667-1672
56.许涛,张小静,王峰,等.肝细胞癌中NY-SAR-35、NY-TLU-57和NY-ESO-1基因的表达及意义.中国肿瘤临床, 2006, 33(10): 545-548
57. Korangy E, Ornandy LA, Bleck JS,et al. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatoeellular carcinoma. Clin cancer Res, 2004, 10(13): 4332-4341
58.刑宝才,袁艳华,胡治国,等. NY-ESO-1/LAGE基因在肝癌组织中的表达及其诱导的免疫应答.中华医学杂志, 2004, 84(23): 1980-1982
59.张文敏,肖刚,谢丹,等.肝细胞癌NY-ESO-1基因/蛋白表达与临床病理特征及肿瘤转移的关系.癌症, 2005, 24(5): 622-626
60. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A. 1997, 94(5): 1914-1918
61.张文敏,肖刚,张萌,等. NY-ESO-1和LAGE-1癌症-睾丸抗原在肝细胞癌的表达.中华病理学杂志, 2005, 34(4): 202-205
62.王万祥,欧阳晓辉,孟兴凯,等. CT9和CT10基因在肝细胞癌中的表达及临床意义.中华肝胆外科杂志, 2006, 12(12): 838-840
63.王万祥,彭吉润,冷希圣,等. HCA587基因在肝细胞癌中的表达及生物信息学分析.内蒙古医学院学报, 2004, 26(4):237-241
64. Martelange V, De Smet C, De Plaen E, et al. Identification on a human sarcoma of two new genes with tumor-specific expression. Cancer Res, 2000, 60(14): 3848-3855.
65. Ono T, Kurashige T, Harada N, et al. Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen. Proc Natl Acad Sci U S A, 2001, 98(6): 3282-3287
66.范蓉,黄巍,肖绍文,等. OY-TES-1在肝细胞癌中的表达及抗体血清学分析.世界华人消化杂志, 2009, 17(32): 3307-3312
67. Ohta M, Tanaka F, Sadanaga N, et al. Expression of the TRAG-3 gene in human esophageal cancer: the frequent synchronous expression of MAGE-3 gene. Oncol Rep. 2006, 15(6): 1529-1532
68. Wang Y, Han KJ, Pang XW, et al. Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies. J Immunol, 2002, 169(2): 1102-1109
69. Dong XY, Su YR, Qian XP, et al. Identification of two novel CT antigens and their capacity to elicit antibody response in hepatocellular carcinoma patients. Br J Cancer, 2003, 89(2): 291-297
70. 70. Monji M, Nakatsura T, Senju S, et al. Identification of a novel human cancer/testis antigen, KM-HN-1, recognized by cellular and humoral immune responses. Clin Cancer Res. 2004, 10(18 Pt 1): 6047-6057
71. Dong XY, Yang XA, Wang YD, et al. Zinc-finger protein ZNF165 is a novel cancer-testis antigen capable of eliciting antibody response in hepatocellular carcinoma patients. Br J Cancer, 2004, 91(8): 1566-1570
72. Dong XY, Li YY, Yang XA, Chen WF, et al. BJ-HCC-20, a potential novel cancer-testis antigen. Biochem Cell Biol, 2004, 82(5): 577-582
73. Yin YH, Li YY, Qiao H, et al. TSPY is a cancer testis antigen expressed in human hepatocellular carcinoma. Br J Cancer, 2005, 93(4): 458-463
74. Tanaka R, Ono T, Sato S, et al. Over-expression of the testis-specific gene TSGA10 in cancers and its immunogenicity. Microbiol Immunol, 2004, 48(4): 339-345
75. Dong XY, Peng JR, Ye YJ, et al. Plac1 is a tumor-specific antigen capable of eliciting spontaneous antibody responses in human cancer patients. Int J Cancer, 2008, 122(9): 2038-2043
76. Watanabe T, Suda T, Tsunoda T, Identification of immunoglobulin superfamily 11 (IGSF11) as a novel target for cancer immunotherapy of gastrointestinal and hepatocellular carcinomas. Cancer Sci, 2005, 96(8): 498-506
77. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci, 2009, 100(11): 2014-2021
78.邵俊斌,陈智.肝癌细胞株中肿瘤特异性抗原MAGA、GAGE、BAGE基因表达的研究.中华肝脏病杂志, 2003, 11(3): 142- 144
79.肖江,陈红松,费然,等.黑色素瘤相关抗原A-1在肝癌细胞株中的表达与基因甲基化程度的相关性.中华肝脏病杂志, 2005, 13(5): 351-354
80. Mou DC, Cai SL, Peng RJ, et al. Evaluation of MAGE-1and MAGE-3 as tumour-specific markers to detect blood dissemination of hepatocellular carcinoma. Br J Cancer, 2002, 86(1): 110-116
81.彭吉润,赵力,牟东成,等.以肿瘤-睾丸抗原mRNA为特异性标记评价肝癌患者肝移植的预后.中华普通外科杂志, 2004, 19(8): 464-467
82. Nakamura S, Nouso K, Noguchi Y, et al. Expression and immunogenicity ofNY-ESO-1 in hepatocellular carcinoma. J Gastroenterol Hepatol, 2006, 21(8): 1281-1285
83. Jeng YM, Chang CC, Hu FC, et al. RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology, 2008, 48(4): 1118-1127
84.肖刚,谭敏,胡少为,等. MAGE-A3在肝癌组织中的表达及意义. 2008, 29(7): 1109-1111
85. Li B, Qian XP, Pang XW, et al. HCA587 antigen expression in normal tissues and cancers: correlation with tumor differentiation in hepatocellular carcinoma. Lab Invest, 2003, 83(8): 1185-1192
86. Yang XA, Dong XY, Qiao H, et al. Immunohistochemical analysis of the expression of FATE/BJ-HCC-2 antigen in normal and malignant tissues. Lab Invest, 2005, 85(2): 205-213
87.刘彬彬,叶胜龙,贺平,等. MAGE-1诱导的树突状细胞体外诱导杀伤人肝癌.细胞中华肝脏病杂志, 2001, 9(3): 151-153
88.郭爱林,隋延仿,叶菁,等.一个新的MAGE-1表位为肝癌细胞表面HLA-B7分子递呈.中国免疫学杂志, 2001, 17(5): 253-255
89.王远,朱继业,彭吉润,等.应用CT抗原肽诱导肝癌患者特异性细胞毒反应的研究.肝胆外科杂志, 2003, 11(1): 29-32
90.陈红松,张华刚,梅铭惠,等. NY-ESO-1和MAGE-A3抗原肽诱导肝癌患者的免疫应答研究.免疫学杂志, 2006, 22(6): 659-663
91. Korangy F, Ormandy LA, Bleck JS, et al. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res, 2004, 10(13): 4332-4341
92. Bricard G, Bouzourene H, Martinet O, et al. Naturally acquired MAGE-A10-and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma. J Immunol, 2005, 174(3): 1709-1716
93. Jager E, Stocken E, Zidianakis Z, et a1.Humoral immuneresponses of cancer patients agains“tCancer-Testis”antigen NY-ESO-1:correlation with clinical events. Int J Cancer, 1999, 84(5): 506-510
94. Zhang JY, Chan EK, Peng XX, et al. Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies. Clin Immunol, 2001, 100(2): 149-156
95. Gnjatic S, Nishikawa H, Jungbluth AA, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res, 2006, 95: 1-30
96.彭吉润,冷圣希. NY-ESO-1抗原与肿瘤免疫治疗进展.中国医学科学院学报, 2008, 30(4): 371-377
1. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA, 1997, 94(5): 1914-1918
2. Jager E, Chen YT, Drijfhout JW, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med, 1998, 187(2): 265-270
3. Nicholaou T, Ebert L, Davis ID, et al. Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. Immunol Cell Biol, 2006, 84(3): 303-317
4. Gnjatic S, Nishikawa H, Jungbluth AA, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res. 2006, 95: 1-30
5. Gnjatic S, Nagata Y, Jager E, et al. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc Natl Acad Sci USA, 2000, 97(20): 10917-10922
6. Slager EH, van der Minne CE, et al. Induction of CAMEL/NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber. Cancer Gene Ther, 2004, 11(3): 227-236
7. Jager E, Jager D, Karbach J, et al. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4+ T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med, 2000, 191(4): 625-630
8. Hasegawa K, Noguchi Y, Koizumi F, et al. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope. Clin Cancer Res, 2006, 12(6): 1921-1927
9. Karbach J, Pauligk C, Bender A, et al. dentification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011. Int J Cancer, 2006, 118(3): 668-674
10. Zarour HM, Storkus WJ, Brusic V, et al. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res, 2000, 60(17): 4946-4952
11. Zeng G, Touloukian CE, Wang X, et al. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol, 2000, 165(2): 1153-1159
12. Mandic M, Castelli F, Janjic B, et al. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J Immunol, 2005, 174(3): 1751-1759
13. Ohkuri T, Sato M, Abe H, et al. Identification of a novel NY-ESO-1 promiscuous helper epitope presented by multiple MHC class II molecules found frequently in the Japanese population. Cancer Sci, 2007, 98(7): 1092-1098
14. Zeng G, Wang X, Robbins PF, et al. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci U S A, 2001, 98(7): 3964-3969
15. Matsuzaki J, Qian F, Luescher I, et al. Recognition of naturally processed and ovarian cancer reactive CD8(+) T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1. Cancer Immunol Immunother. 2008, 57(8): 1185-1195
16. Jager E, Gnjatic S, Nagata Y, et al. Induction of primary NY-ESO-1 immunity: CD8+ T lumphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA, 2000, 97(22): 12198-12203
17. Odunsi K, Qian F, Matsuzaki J, et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A, 2007, 104(31): 2837-12842
18. Bender A, Karbach J, Neumann A, et al. LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. Cancer Immun. 2007, 7: 16
19. Chen JL, Dunbar PR, Gileadi U, et al. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol, 2000, 165(2): 948-955
20.陈红松,张华刚,梅铭惠,等. NY-ESO-1和MAGE-A3抗原肽诱导肝癌患者的免疫应答研究.免疫学杂志, 2006, 22(6): 659-663
21. Susumu S, Nagata Y, Ito S, et al. Cross-presentation of NY-ESO-1 cytotoxic T lymphocyte epitope fused to human heat shock cognate protein 70 by dendritic cells. Cancer Sci. 2008 99(1): 107-112
22. Shackleton M, Davis ID, Hopkins W, et al. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun, 2004, 4: 9
2. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA, 1997, 94: 1914-1910
3. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun, 2004, 4: 1
4. Old LJ. Cancer vaccine collaborative 2002: Opening address. Cancer Immun, 2003, 3(Suppl 1): 1
5. Ono T, Kurashige T, Harada N, et al. Identification binding protein sp32 precursor as a human cancer/testis antigen. Proc Natl Acad Sci USA, 2001, 98(6): 3282-3287
6. Baba T, Michikawa Y, Kashiwabara S, et al. Proacrosin activation in the presence of a 32-kDa protein from boar spermatozoa. Biochem Biophys Res Commun, 1989,160(3): 1026 -1032
7. Baba T, Niida Y, Michikawa Y, et al. An acrosomal protein, sp32, in mammalian sperm is a binding protein specific for two proacrosins and an acrosin intermediate. J Biol Chem. 1994, 269(13): 10133-10140
8. Tardif S, DubéC, Chevalier S, et al. Capacitation is associated with tyrosine phosphorylation and tyrosine kinase-like activity of pig sperm proteins. Biol Reprod, 2001, 65(3): 784 -792
9.范蓉,罗彬,谢小薰.精子蛋白32研究进展.解剖学杂志. 2007, 30(4): 503-505
10. Kubuschok B, Xie X, Jesnowski R, et al. Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis. Int J Cancer, 2004, 109(4): 568-575
11.范蓉,肖绍文,何少健,等.精子蛋白Sp32/OY-TES-1基因mRNA表达的初步研究.解剖学报, 2006, 37(1): 102-105
12. Hofmann O, Caballero OL, Stevenson BJ, et al. Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A. 2008, 105(51): 20422-20427
13.范蓉,余良,肖绍文,等.实时荧光定量PCR分析精子蛋白Sp32/OY-TES-1基因在正常组织的表达.解剖学报, 2007, 30(4): 81-84
14. Tammela J, Uenaka A, Ono T, et al. OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer. Int J Oncol, 2006, 29(4): 903-910
15.王峰,范蓉,莫发荣,等.癌-睾丸抗原OY-TES-1基因的克隆、表达及纯化.中国免疫学杂志, 2006, 22(12): 16-19
16.范蓉,肖绍文,黄巍,等.癌-睾丸抗原OY-TES-1多克隆抗体的制备及鉴定.中国生物制品学杂志, 2009, 22(8): 804-807
17.范蓉,黄巍,肖绍文,等. OY-TES-1在肝细胞癌中的表达及抗体血清学分析.世界华人消化杂志, 2009, 17(32): 3307-3312
18.范蓉.癌-睾丸抗原OY-TES-1基因重组、表达及抗体血清学分析[博士学位论文].广西医科大学, 2007
19. Okumura H, Nagushi Y, Uanaha A, et al. Identification of an HLA-A24-restricted OY-TES-1 epitope recognized by cytotoxic T cell.Microbiol Immunol, 2005, 49(11): 1009-1016
20. Cronwright G, Le Blanc K, Gotherstrom C, et al. Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSXimpairs cell migration and matrix metalloproteinase 2 expression. Cancer Res, 2005, 65(6): 2207-2215
21. Cilensek ZM, Yehiely F, Kular RK, et al. A member of the GAGE family of tumor antigens is an anti-apoptotic gene that confers resistance to Fas/CD95/APO-1, Interferon-gamma, taxol and gamma-irradiation. Cancer Biol Ther. 2002, 1(4): 380-387
22. Kular RK, Yehiely F, Kotlo KU, et al. GAGE, an antiapoptotic protein binds and modulates the expression of nucleophosmin/B23 and interferon regulatory factor 1. J Interferon Cytokine Res, 2009, 29(10): 645-655
23.蔡三军主编.结直肠肛管癌.北京:北京大学医学出版社, 2006, 11-365
24. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell, 1996, 87(2): 159-170
25.何理盛主编.脑膜瘤.北京:人民卫生出版社, 2003, 4-224
26. Peng JR, Chen HS, Mou DC, et al. Expression of cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and its correlation with clinical parameters. Cancer Lett, 2005, 219(2): 223-232
27. Grizzi F, Franceschini B, Hamrick C, et al. Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma. J Transl Med, 2007, 5: 3
28. Gure AO, Stockert E, Arden KC, et al. CT10: a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational difference analysis. Int J Cancer, 2000, 85: 726-732
29.冯作化主编.医学分子生物学.北京:人民卫生出版社,2005, 175-190
30. http://www.clontech.com/images/pt/dis_vectors/PT3233-5.pdf
31. Zhang J,Cmapbeu RE,Ting AY,et al. Creating new fluorescent probe so freel biology. Nat Rev Mol Cel lBiol, 2002, 3: 906-918
32. Kozak M.Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell, 1986, 44(2): 283-292
33. Kozak M. At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J Mol Biol, 1987,196(4): 947-950
34. Kozak M. Pushing the limits of the scanning mechanism for initiation of translation. Gene, 2002, 299(1-2): 1-34
35.高川,王惠芳,张靖.脂质体介导转染法的原理与应用.生命的化学, 2002, 22(1): 73-75
36.吴海霞,张维铭,李晓眠.基因转染技术的现状与发展.国际生物医学工程杂志, 2007, 30(6): 376-379
37. Calvin S, Calvin JE, Wang J,et al. FuGENE?? HD Transfection Reagent: Choice of a Transfection Reagent with Minimal Off-Target Effect as Analyzed by Microarray Transcriptional Profiling. Biochemica, 2006, 4: 22-26
38. Jacobsen L, Calvin S, Lobenhofer E, et al. Transcriptional effects of transfection: the potential for misinterpretation of gene expression data generated from transiently transfected cells. Biotechniques, 2009, 47(1): 617-624
39.邵英光,李京华,魏桂林,等.内毒素的去除策略.广州化学, 2003, 28(2): 36-45
40. Calvin S, Pitz S, Jacobsen L. Enabling Cancer Research with FuGENE? HD Transfection Reagent. Biochemica, 2007, 2: 26-29
41. Fillion-FortěV, Mounier C. Optimization of transfection efficiency in chick embryo hepatocytes and HepG2 cells. Biochemica, 2007, 1: 13-15
42.姜泊,张亚历,周殿元主编.分子生物学常用实验方法.北京:人民军医出版社, 1996, 159
43.鄂征主编.组织培养技术及其在医学研究中的作用.北京:中国协和医学大学出版社, 2004, 10-133
44. Van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 1991, 254(5038): 1643-1647
45.范蓉,罗昱,肖绍文.肿瘤-睾丸抗原的特性及临床应用.国外医学肿瘤学分册, 2005, 32(3): 166-169
46. Laduron S, Dep lus R, Zhou S, et al. MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucleic Acids Res, 2004, 32 (14) : 4340-4350
47. Sakurai T, Itoh K, Higashitsuji H, et al. A cleaved form of MAGE-A4 binds to Miz-1 and induces apoptosis in human cells. J Biol Chem, 2004, 279(15): 15505-15514
48. Nagao T, Higashitsuji H, Nonoguchi K, et al. MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity. J Biol Chem, 2003, 278(12): 10668-10674
49. Peikert T, Specks U, Farver C, et al. Melanoma antigen A4 is expressed in non-small cell lung cancers and promotes apoptosis. Cancer Res, 2006, 66(9): 4693-4700
50. Li J, Tsai MD. Novel insights into the INK4-CDK4/6-Rb pathway: counter action of gankyrin against INK4 proteins regulates the CDK4-mediated phosphorylation of Rb. Biochemistry, 2002, 41(12): 3977-3983
51. Simpson AJ, Caballero OL, Jungbluth A, et al. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer, 2005, 5(8): 615-625
52. Kular RK, Yehiely F, Kotlo KU, et al. GAGE, an antiapoptotic protein bindsand modulates the expression of nucleophosmin/B23 and interferon regulatory factor 1. J Interferon Cytokine Res, 2009, 29(10): 645-655
53. Shim H, Shim IE, Lee H, et al. CAGE, a novel cancer/testis antigen gene, promotes cell motility by activating ERK and p38 MAPK and down regulating ROS. Mol Cells, 2006, 21 (3): 367-371
54. Shim H, Lee H, Jeoung D. Cancer/testis antigen cancer-associated gene (CAGE) promotes motility of cancer cells through activation of focal adhesion kinase (FAK). Biotechnol Lett, 2006, 28(24): 2057-2063
55. Kim Y, Jeoung D. The cancer/testis antigen CAGE induces MMP-2 through the activation of NF-kappaB and AP-1. BMB Rep. 2009, 42(11): 758-763
56. Duan Z, Duan Y, Lamendola DE, et al. Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res, 2003, 9(7): 2778-2785
57.宋玉亮,彭思扬,王晨滔. XAGE-1b腺病毒表达载体的构建及其功能研究.复旦学报(自然科学版), 2008, 47(3): 318-324
58.曾益新主编.肿瘤学.第二版.北京:人民卫生出版社, 2003,157-158
59.宋今丹主编.医学细胞分子生物学.北京:人民卫生出版社, 2003, 389
60. AJCC. AJCC cancer staging manual. Fifth edition. Philadelphia: Lippincott, 1997
61. Dukes CE. Cancer of the rectum: an analysis of 1000 cases. J. Pathol Bacteriol, 1940, 50: 527
62. Shimizu M, Saitoh Y, Itoh H. Immunohistochemical staining of Ha-ras oncogene product in normal, benign, and malignant human pancreatic tissue. Hum Pathol, 1990, 21(6):607-612
63. Kr?mer BF, Schoor O, Krüger T, et al. MAGED4-expression in renal cell carcinoma and identification of an HLA-A*25-restricted MHC class I ligandfrom solid tumor tissue. Cancer Biol Ther. 2005, 4(9):943-948
64.邢传平,刘斌,董亮.免疫组织化学标记结果的判断方法.中华病理学杂志, 2001, 30(4): 318
65.许良中,杨文涛.免疫组织化学反应结果的判断标准.中国癌症杂志, 1996, 6(4): 229-231
66. Parkin DM. Global cancer statistics in the year 2000. Laucet Oncol, 2001, 2: 533-543
67. Chen Z, Li M, Yuan Y, et al. Cancer/testis antigens and clinical risk factors for liver metastasis of colorectal cancer: a predictive panel. Dis Colon Rectum, 2010, 53(1): 31-38
68. Burgdorf SK, Fischer A, Myschetzky PS, et al. Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine. Oncol Rep, 2008, 20(6): 1305-1311
69. Alves PM, Lévy N, Bouzourene H, Viatte S, et al. Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer. Cancer Immunol Immunother, 2007, 56(6):839-847
70. Dakshinamurthy AG, Ramesar R, Goldberg P, et al. Infrequent and low expression of cancer-testis antigens located on the X chromosome in colorectal cancer: implications for immunotherapy in South African populations. Biotechnol J, 2008,3(11): 1417-1423
71.熊永炎,宗永生.肿瘤异质性研究进展.国外医学肿瘤学分册, 1992, 19(4): 208-211
72. Berchuck A,Olt GJ,Soisson AP,et al. Heterogeneity of antigen expression in advanced epithelial ovarian cancer. Am J Obstet Gynecol,1990,162(4):883-888
73. KariyamaK,Higashi T, KobayashiY,et al. Expression of MAGE-1 and -3 genes and gene products in human hepatocellular carcinoma. Br J Cancer,1999, 81(6): 1080-1087
74. Alves PM, Lévy N, Bouzourene H, et al. Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer. Cancer Immunol Immunother, 2007, 56(6): 839-847
75.李世荣主编,大肠癌—早期诊断、治疗和预防.北京:科学出版社, 2000, 81
76. Norden AD, Drappatz J, Wen PY. Advances in meningioma therapy. Curr Neurol Neurosci Rep, 2009, 9(3): 231-240
77. Rockhill J, Mrugala M, Chamberlain MC. Intracranial meningiomas: an overview of diagnosis and treatment. Neurosurg Focus, 2007, 23(4): E1
78.黄文清主编.神经肿瘤病理学(第二版).军事医学科学出版社,北京, 2001, 479-506
79.王峰,范蓉,谢小薰.CT抗原-神经系统肿瘤免疫治疗的新靶向.肿瘤防治研究, 2007, 34(2): 154-156
80. Sahin U, Koslowski M, Türeci O, et al. Expression of cancer testis genes in human brain tumors. Clin Cancer Res, 2000, 6(10):3916-3922
81. Lee MH, Son EI, Kim E, et al. Expression of cancer-testis genes in brain tumors. J Korean Neurosurg Soc, 2008, 43(4): 190-193
82. Chi DD, Merchant RE, Rand R, et al. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol, 1997, 150(6): 2143-2152
83. Grizzi F, Gaetani P, Franceschini B, et al. Sperm protein 17 is expressed in human nervous system tumours. BMC Cancer. 2006, 6: 23
84.高飞,由田,吕晶玉,等. CAGE基因在颅脑肿瘤中的表达及其机制.癌变畸变突变, 19(3): 239-241
85.范蓉,肖绍文,罗昱,等.癌-睾丸抗原基因NY-SAR-35在人脑膜瘤中的表达.中华神经外科杂志, 2005, 21(2): 109
86. John R. Crowther. The ELISA Guidebook, USA: Humana Press Inc, 2001, 131
87. Houghton AN, Guevara-Patino JA. Immune recognition of self in immunity against cancer. J Clin Invest, 2004,114(4): 551-559
88. Fernandez Madrid F, Tang N, Alansari H, et al. Autoantibodies to Annexin XI-A and Other Autoantigens in the Diagnosis of Breast Cancer. Cancer Res, 2004, 64(15): 5089-5096
89. Coronella JA, Hersh EM. Naturally occurring B cell responses to breast cancer. Cancer Immunol Immunother, 2003, 52(12): 715-738
90.冉宇靓,胡海,赵泽国,等.结肠癌肿瘤自身抗体谱筛选及其应用.肿瘤防治研究, 2008, 35(5): 328-331, 346
91.吴晓江,王歈,季加孚.胃癌中肿瘤/睾丸抗原的表达研究及NY-ESO-1蛋白的自身抗体检测.北京大学学报, 2005, 37(3): 252-256
92. Mathieu MG, Miles AK, Li G, et al. Cancer/testis antigens for therapeutic use. J BUON, 2009, Suppl 1: S97-102
93. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci, 2009, 100(11): 2014-2021
94. Ghafouri-Fard S, Modarressi MH. Cancer-testis antigens: potential targets for cancer immunotherapy. Arch Iran Med, 2009, 12(4): 395-404
95. Zhou SF, Xie XX, Bin YH, et al. ,Identification of HCC-22-5 tumor-associated antigen and antibody response in patients. Clin Chim Acta, 2006, 366(1-2): 274-280
96.谢小薰,王延伟,黎鹏,等.肝细胞癌动力素抗体的血清学分析.中华消化杂志, 2003, 23(12): 751-752
97. Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon Rectum, 1994 ,37(3):272-277
98. Chapman MA, Buckley D, Henson DB, et al. Preoperative carcinoembryonic antigen is related to tumour stage and long-term survival in colorectal cancer. Br J Cancer, 1998, 78(10):1346-1349
99. Heckel D, Comtesse N, Brass N, et al. Novel immunogenic antigen homologous to hyaluronidase in meningioma. Hum Mol Genet, 1998, 7(12):1859-1872
100.Comtesse N, Niedermayer I, Glass B, et al.MGEA6 is tumor-specific overexpressed and frequently recognized by patient-serum antibodies. Oncogene, 2002, 21(2): 239-247
101.Comtesse N, Zippel A, Walle S, Complex humoral immune response against a benign tumor: frequent antibody response against specific antigens as diagnostic targets. Proc Natl Acad Sci U S A, 2005, 102(27):9601-9606
102.S?ling A, Plugge EM, Schmitz M, Autoantibodies to the inhibitor of apoptosis protein survivin in patients with brain tumors. nt J Oncol, 2007, 30(1): 123-128
103. Lea IA, Adoyo P, O'Rand MG. Autoimmunogenicity of the human sperm protein Sp17 in vasectomized men and identification of linear B cell epitopes. Fertil Steril. 1997, 67(2): 355-361
104.范蓉,黄巍,肖绍文,等.精子蛋白32(sp32)/OY-TES-1在生精细胞中的分布及其抗体的血清学检测.生殖与避孕, 29(6): 365-369
105.Lu H, Goodell V, Disis ML. Humoral Immunity Directed against Tumor-Associated Antigens As Potential Biomarkers for the Early Diagnosis of Cancer. J Proteome Res. 2008, 7(4): 1388-1394
106.Gadducci A, Ferdeghini M, Buttitta F, et al. Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer. Gynecol Oncol, 1999, 72(1): 76-81
107.Lechpammer M, Lukac J, Lechpammer S, et al. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Int J Colorectal Dis, 2004, 19(2): 114-120
108.J?ger D, Stockert E, Güre AO, et al. Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Res. 2001, 61(5): 2055-2061
109.Stockert E, J?ger E, Chen YT, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med, 1998, 187(8): 1349-1354
110.Jager E, Stocken E, Zidianakis Z, et a1.Humoral immuneresponses of cancer patients agains“tCancer-Testis”antigen NY-ESO-1:correlation with clinical events. Int J Cancer, 1999, 84(5): 506-510
1.石永玉,王宏程,李燕,等.肝癌相关的肿瘤抗原及其编码基因的筛选与分析.科学通报, 2003, 48(6): 1772-1775
2. Shi YY, Wang HC, Yin YH, et al. Identification and analysis of tumour-associated antigens in hepatocellular carcinoma. Br J Cancer, 2005, 92(5): 929-934
3. Zerbini A, Pilli M, Ferrari C, et al. Is there a role for immunotherapy in hepatocellular carcinoma? Dig Liver Dis, 2006, 38(4): 221-225
4. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun, 2004, 4: 1
5. Van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 1991, 254(5038): 1643-1647
6. Ghafouri-Fard S, Modarressi MH. Cancer-testis antigens: potential targets for cancer immunotherapy. Arch Iran Med, 2009, 12(4): 395-404.
7. Almeida LG, Sakabe NJ, Oliveira AR, et al. CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res, 2009, 37: D816-819
8. Simpson AJ, Caballero OL, Jungbluth A, et al. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer, 2005, 5(8): 615-625
9.彭吉润,郭立民,陈红松,等.肿瘤-睾丸抗原与肿瘤免疫治疗.继续医学教育, 2006, 20(9): 45-48
10.杨丽,王建军,郑英.肿瘤/睾丸抗原研究进展.医学研究杂志, 2008, 37(1): 13-16
11. Modarressi MH, Cameron J, Taylor KE, et al. Identification andcharacterisation of a novel gene, TSGA10, expressed in testis. Gene, 2001, 262(1-2): 249-255
12. Modarressi MH, Behnam B, Cheng M, et al. Tsga10 encodes a 65-kilodalton protein that is processed to the 27-kilodalton fibrous sheath protein. Biol Reprod, 2004, 70(3): 608-615
13. Türeci O, Sahin U, Schobert I, et al. The SSX-2 gene, which is involved in the t (X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res, 1996, 56(20): 4766-4772
14. Türeci O, Sahin U, Koslowski M, et al. A novel tumour associated leucine zipper protein targeting to sites of gene transcription and splicing. Oncogene, 2002, 21(24): 3879-3888
15. Pointud JC, Mengus G, Brancorsini S, et al. The intracellular localisation of TAF7L, a paralogue of transcription factor TFIID subunit TAF7, is developmentally regulated during male germ-cell differentiation. J Cell Sci, 2003, 116(Pt 9): 1847-1858
16. Scanlan MJ, Altorki NK, Gure AO, et al. Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. Cancer Lett, 2000, 150(2): 155-164
17. Pivot-Pajot C, Caron C, Govin J, et al. Acetylation-dependent chromatin reorganization by BRDT, a testis-specific bromodomain-containing protein. Mol Cell Biol, 2003, 23(15): 5354-5365
18. Scibetta AG, Santangelo S, Coleman J, et al. Functional analysis of the transcription repressor PLU-1/JARID1B. Mol Cell Biol, 2007, 27(20): 7220-7235
19. Kang Y, Hong JA, Chen GA, et al. Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1expression in lung cancer cells. Oncogene, 2007, 26(30): 4394-4403
20. Herold A, Suyama M, Rodrigues JP, et al. TAP (NXF1) belongs to a multigene family of putative RNA export factors with a conserved modular architecture. Mol Cell Biol, 2000, 20(23): 8996-9008
21. 21. Scanlan MJ, Gordon CM, Williamson B, et al. Identification of cancer/testis genes by database mining and mRNA expression analysis. Int J Cancer, 2002, 98(4): 485-492
22. Krupnik VE, Sharp JD, Jiang C, et al. Functional and structural diversity of the human Dickkopf gene family. Gene, 1999, 238(2): 301-313
23. Laduron S, Dep lus R, Zhou S, et al. MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucleic Acids Res, 2004, 32 (14): 4340-4350
24. Martelange V, De Smet C, De Plaen E, et al. Identification on a human sarcoma of two new genes with tumor-specific expression. Cancer Res, 2000, 60(14): 3848-3855
25. De Jong A, Buchli R, Robbins D. et al. Characterization of sperm protein 17 in human somatic and neoplastic tissue. Cancer Lett, 2002, 186(2): 201-209
26. Kr?tzschmar J, Haendler B, Eberspaecher U, et al. The human cysteine-rich secretory protein (CRISP) family. Primary structure and tissue distribution of CRISP-1, CRISP-2 and CRISP-3. Eur J Biochem, 1996, 236(3): 827-836
27. Shan J, Yuan L, Xiao Q, et al. TSP50, a possible protease in human testes, is activated in breast cancer epithelial cells. Cancer Res, 2002, 62(1): 290-294
28. Koslowski M, Türeci O, Bell C, et al. Multiple splice variants of lactate dehydrogenase C selectively expressed in human cancer. Cancer Res, 2002, 62(22): 6750-6755
29. Cho B, Lim Y, Lee DY, et al. Identification and characterization of a novelcancer/testis antigen gene CAGE. Biochem Biophys Res Commun, 2002, 292(3): 715-726
30. Cilensek ZM, Yehiely F, Kular RK, et al. A member of the GAGE family of tumor antigens is an anti-apoptotic gene that confers resistance to Fas/CD95/APO-1, Interferon-gamma, taxol and gamma-irradiation. Cancer Biol Ther, 2002, 1(4): 380-387
31. Pousette A, Leijonhufvud P, Arver S, et al. Presence of synaptonemal complex protein 1 transversal filament-like protein in human primary spermatocytes. Hum Reprod, 1997, 12(11): 2414-2417
32. Keeney S, Giroux CN, Kleckner N. Meiosis-specific DNA double-strand breaks are catalyzed by Spo11, a member of a widely conserved protein family. Cell, 1997, 88(3): 375-384
33. Luo G, Huang S, Xie X, et al. Expression of cancer-testis genes in human hepatocellular carcinomas. Cancer Immun, 2002, 2: 11
34. Suzuki K, Tsujitani S, Konishi I, et al. Expression of MAGE genes and survival in patients with hepatocellular careinoma. Int J oncol, 1999, 15(6): 1227-1232
35.谢小薰,蓝玲,黎鹏,等.多种癌-睾丸抗原在广西肝细胞癌中的表达.中华消化杂志, 2004, 24(3): 174- 175
36.谢小薰,何少健,肖绍文,等.三种MAGE基因在广西肝细胞癌中的表达.肿瘤, 2005, 25(6): 585-588
37.刘彬彬,叶胜龙,贺平,等. MAGE-1基因在肝细胞性肝癌中的表达.中华肝脏病杂志, 1999, 7(2): 91-93
38.陈红松,覃柳亮,丛旭,等.肿瘤特异性肿瘤/睾丸抗原在肝癌组织中的表达.中国肝脏病杂志, 2003, 11(3): 145-148
39.肖刚,张文敏,张萌,等.肝癌组织中MAGE-Al表达及其临床意义.临床与实验病理学杂志, 2005, 20(3): 332-334
40. Tahara K, Mori M, Sadanaga N, et al. Expression of the MAGE gene family in human hepatocellular carcinoma. Cancer, 1999, 85(6): 1234-1240
41. Peng JR, Chen HS, Mou DC, et al. Expression of cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and its correlation with clinical parameters. Cancer Lett, 2005, 219(2): 223-232
42.蔡胜利,陈红松,王瑜,等.黑色素瘤抗原1基因在肝细胞癌中的表达.中华医学杂志, 1999, 79(9): 668-672
43.蔡胜利,陈红松,王瑜,等.恶性黑色素瘤抗原编码基因MAGE-1在肝细胞癌中表达的研究.中华普通外科杂志, 1999, 14(3): 229-230
44.牟东成,冷希圣,彭润吉,等.黑色素瘤抗原MAGE-B亚家族基因在肝细胞癌中的表达.中华肿瘤杂志, 2004, 26(1): 40-42
45. Zhao L, Mou DC, Leng XS, et al. Expression of cancer-testis antigens in hepatocellular carcinoma. World J Gastroenterol 2004, 10(14): 2034-2038
46. Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol, 1997, 9(5): 684-693
47. Riener MO, Wild PJ, Soll C, et al. Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma. Int J Cancer. 2009, 124(2): 352-357
48.赵飞兰,何少健,黎鹏,等.癌-睾丸抗原GAGE基因mRNA在肝细胞癌表达及临床意义.中华肝脏病杂志, 2006, 14(8): 605-606
49. Wang XY, Chen HS, Luo S, et al. Comparisons for detecting NY-ESO-1 mRNA expression levels in hepatocellular carcinoma tissues. Oncol Rep, 2009, 21(3): 713-719
50.张小静,范蓉,何少健,等.癌-睾丸抗原SSX基因在肝细胞癌中的表达及临床意义.世界华人消化杂志, 2009, 17(19): 2000-2004
51.吴力群,王新建,卢云,等.肝细胞肝癌患者肿瘤/睾丸抗原SSX-1及NY-ESO-1 mRNA的表达意义.世界华人消化杂志, 2005, 13(14): 1673-1678
52.易斌,廖晓峰,杨志芳,等.肿瘤—睾丸抗原SSX1和SSX4 mRNA在肝细胞癌中的表达.华中科技大学学报, 2006, 35(1): 63-65
53. Chen CH, Chen GJ, Lee HS, et al. Expressions of cancer-testis antigens in human hepatocellular carcinomas. Cancer Lett, 2001, 164(2): 189-195
54. Türeci O, Chen YT, Sahin U, et al. Expression of SSX genes in human tumors. Int J Cancer, 1998, 77(1): 19-23
55.吴力群,王新建,张斌.肝细胞癌组织和外周血中肿瘤/睾丸抗原SSX-2和SSX-5的表达.世界华人消化杂志, 2005, 13(14): 1667-1672
56.许涛,张小静,王峰,等.肝细胞癌中NY-SAR-35、NY-TLU-57和NY-ESO-1基因的表达及意义.中国肿瘤临床, 2006, 33(10): 545-548
57. Korangy E, Ornandy LA, Bleck JS,et al. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatoeellular carcinoma. Clin cancer Res, 2004, 10(13): 4332-4341
58.刑宝才,袁艳华,胡治国,等. NY-ESO-1/LAGE基因在肝癌组织中的表达及其诱导的免疫应答.中华医学杂志, 2004, 84(23): 1980-1982
59.张文敏,肖刚,谢丹,等.肝细胞癌NY-ESO-1基因/蛋白表达与临床病理特征及肿瘤转移的关系.癌症, 2005, 24(5): 622-626
60. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A. 1997, 94(5): 1914-1918
61.张文敏,肖刚,张萌,等. NY-ESO-1和LAGE-1癌症-睾丸抗原在肝细胞癌的表达.中华病理学杂志, 2005, 34(4): 202-205
62.王万祥,欧阳晓辉,孟兴凯,等. CT9和CT10基因在肝细胞癌中的表达及临床意义.中华肝胆外科杂志, 2006, 12(12): 838-840
63.王万祥,彭吉润,冷希圣,等. HCA587基因在肝细胞癌中的表达及生物信息学分析.内蒙古医学院学报, 2004, 26(4):237-241
64. Martelange V, De Smet C, De Plaen E, et al. Identification on a human sarcoma of two new genes with tumor-specific expression. Cancer Res, 2000, 60(14): 3848-3855.
65. Ono T, Kurashige T, Harada N, et al. Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen. Proc Natl Acad Sci U S A, 2001, 98(6): 3282-3287
66.范蓉,黄巍,肖绍文,等. OY-TES-1在肝细胞癌中的表达及抗体血清学分析.世界华人消化杂志, 2009, 17(32): 3307-3312
67. Ohta M, Tanaka F, Sadanaga N, et al. Expression of the TRAG-3 gene in human esophageal cancer: the frequent synchronous expression of MAGE-3 gene. Oncol Rep. 2006, 15(6): 1529-1532
68. Wang Y, Han KJ, Pang XW, et al. Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies. J Immunol, 2002, 169(2): 1102-1109
69. Dong XY, Su YR, Qian XP, et al. Identification of two novel CT antigens and their capacity to elicit antibody response in hepatocellular carcinoma patients. Br J Cancer, 2003, 89(2): 291-297
70. 70. Monji M, Nakatsura T, Senju S, et al. Identification of a novel human cancer/testis antigen, KM-HN-1, recognized by cellular and humoral immune responses. Clin Cancer Res. 2004, 10(18 Pt 1): 6047-6057
71. Dong XY, Yang XA, Wang YD, et al. Zinc-finger protein ZNF165 is a novel cancer-testis antigen capable of eliciting antibody response in hepatocellular carcinoma patients. Br J Cancer, 2004, 91(8): 1566-1570
72. Dong XY, Li YY, Yang XA, Chen WF, et al. BJ-HCC-20, a potential novel cancer-testis antigen. Biochem Cell Biol, 2004, 82(5): 577-582
73. Yin YH, Li YY, Qiao H, et al. TSPY is a cancer testis antigen expressed in human hepatocellular carcinoma. Br J Cancer, 2005, 93(4): 458-463
74. Tanaka R, Ono T, Sato S, et al. Over-expression of the testis-specific gene TSGA10 in cancers and its immunogenicity. Microbiol Immunol, 2004, 48(4): 339-345
75. Dong XY, Peng JR, Ye YJ, et al. Plac1 is a tumor-specific antigen capable of eliciting spontaneous antibody responses in human cancer patients. Int J Cancer, 2008, 122(9): 2038-2043
76. Watanabe T, Suda T, Tsunoda T, Identification of immunoglobulin superfamily 11 (IGSF11) as a novel target for cancer immunotherapy of gastrointestinal and hepatocellular carcinomas. Cancer Sci, 2005, 96(8): 498-506
77. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci, 2009, 100(11): 2014-2021
78.邵俊斌,陈智.肝癌细胞株中肿瘤特异性抗原MAGA、GAGE、BAGE基因表达的研究.中华肝脏病杂志, 2003, 11(3): 142- 144
79.肖江,陈红松,费然,等.黑色素瘤相关抗原A-1在肝癌细胞株中的表达与基因甲基化程度的相关性.中华肝脏病杂志, 2005, 13(5): 351-354
80. Mou DC, Cai SL, Peng RJ, et al. Evaluation of MAGE-1and MAGE-3 as tumour-specific markers to detect blood dissemination of hepatocellular carcinoma. Br J Cancer, 2002, 86(1): 110-116
81.彭吉润,赵力,牟东成,等.以肿瘤-睾丸抗原mRNA为特异性标记评价肝癌患者肝移植的预后.中华普通外科杂志, 2004, 19(8): 464-467
82. Nakamura S, Nouso K, Noguchi Y, et al. Expression and immunogenicity ofNY-ESO-1 in hepatocellular carcinoma. J Gastroenterol Hepatol, 2006, 21(8): 1281-1285
83. Jeng YM, Chang CC, Hu FC, et al. RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology, 2008, 48(4): 1118-1127
84.肖刚,谭敏,胡少为,等. MAGE-A3在肝癌组织中的表达及意义. 2008, 29(7): 1109-1111
85. Li B, Qian XP, Pang XW, et al. HCA587 antigen expression in normal tissues and cancers: correlation with tumor differentiation in hepatocellular carcinoma. Lab Invest, 2003, 83(8): 1185-1192
86. Yang XA, Dong XY, Qiao H, et al. Immunohistochemical analysis of the expression of FATE/BJ-HCC-2 antigen in normal and malignant tissues. Lab Invest, 2005, 85(2): 205-213
87.刘彬彬,叶胜龙,贺平,等. MAGE-1诱导的树突状细胞体外诱导杀伤人肝癌.细胞中华肝脏病杂志, 2001, 9(3): 151-153
88.郭爱林,隋延仿,叶菁,等.一个新的MAGE-1表位为肝癌细胞表面HLA-B7分子递呈.中国免疫学杂志, 2001, 17(5): 253-255
89.王远,朱继业,彭吉润,等.应用CT抗原肽诱导肝癌患者特异性细胞毒反应的研究.肝胆外科杂志, 2003, 11(1): 29-32
90.陈红松,张华刚,梅铭惠,等. NY-ESO-1和MAGE-A3抗原肽诱导肝癌患者的免疫应答研究.免疫学杂志, 2006, 22(6): 659-663
91. Korangy F, Ormandy LA, Bleck JS, et al. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res, 2004, 10(13): 4332-4341
92. Bricard G, Bouzourene H, Martinet O, et al. Naturally acquired MAGE-A10-and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma. J Immunol, 2005, 174(3): 1709-1716
93. Jager E, Stocken E, Zidianakis Z, et a1.Humoral immuneresponses of cancer patients agains“tCancer-Testis”antigen NY-ESO-1:correlation with clinical events. Int J Cancer, 1999, 84(5): 506-510
94. Zhang JY, Chan EK, Peng XX, et al. Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies. Clin Immunol, 2001, 100(2): 149-156
95. Gnjatic S, Nishikawa H, Jungbluth AA, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res, 2006, 95: 1-30
96.彭吉润,冷圣希. NY-ESO-1抗原与肿瘤免疫治疗进展.中国医学科学院学报, 2008, 30(4): 371-377
1. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA, 1997, 94(5): 1914-1918
2. Jager E, Chen YT, Drijfhout JW, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med, 1998, 187(2): 265-270
3. Nicholaou T, Ebert L, Davis ID, et al. Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. Immunol Cell Biol, 2006, 84(3): 303-317
4. Gnjatic S, Nishikawa H, Jungbluth AA, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res. 2006, 95: 1-30
5. Gnjatic S, Nagata Y, Jager E, et al. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc Natl Acad Sci USA, 2000, 97(20): 10917-10922
6. Slager EH, van der Minne CE, et al. Induction of CAMEL/NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber. Cancer Gene Ther, 2004, 11(3): 227-236
7. Jager E, Jager D, Karbach J, et al. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4+ T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med, 2000, 191(4): 625-630
8. Hasegawa K, Noguchi Y, Koizumi F, et al. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope. Clin Cancer Res, 2006, 12(6): 1921-1927
9. Karbach J, Pauligk C, Bender A, et al. dentification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011. Int J Cancer, 2006, 118(3): 668-674
10. Zarour HM, Storkus WJ, Brusic V, et al. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res, 2000, 60(17): 4946-4952
11. Zeng G, Touloukian CE, Wang X, et al. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol, 2000, 165(2): 1153-1159
12. Mandic M, Castelli F, Janjic B, et al. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J Immunol, 2005, 174(3): 1751-1759
13. Ohkuri T, Sato M, Abe H, et al. Identification of a novel NY-ESO-1 promiscuous helper epitope presented by multiple MHC class II molecules found frequently in the Japanese population. Cancer Sci, 2007, 98(7): 1092-1098
14. Zeng G, Wang X, Robbins PF, et al. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci U S A, 2001, 98(7): 3964-3969
15. Matsuzaki J, Qian F, Luescher I, et al. Recognition of naturally processed and ovarian cancer reactive CD8(+) T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1. Cancer Immunol Immunother. 2008, 57(8): 1185-1195
16. Jager E, Gnjatic S, Nagata Y, et al. Induction of primary NY-ESO-1 immunity: CD8+ T lumphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA, 2000, 97(22): 12198-12203
17. Odunsi K, Qian F, Matsuzaki J, et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A, 2007, 104(31): 2837-12842
18. Bender A, Karbach J, Neumann A, et al. LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. Cancer Immun. 2007, 7: 16
19. Chen JL, Dunbar PR, Gileadi U, et al. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol, 2000, 165(2): 948-955
20.陈红松,张华刚,梅铭惠,等. NY-ESO-1和MAGE-A3抗原肽诱导肝癌患者的免疫应答研究.免疫学杂志, 2006, 22(6): 659-663
21. Susumu S, Nagata Y, Ito S, et al. Cross-presentation of NY-ESO-1 cytotoxic T lymphocyte epitope fused to human heat shock cognate protein 70 by dendritic cells. Cancer Sci. 2008 99(1): 107-112
22. Shackleton M, Davis ID, Hopkins W, et al. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun, 2004, 4: 9